With third pharma deal, IFM's unorthodox approach paying off

In just three years, Gary Glick and his team at IFM Therapeutics have parlayed their research into three deals with blue-chip pharmaceutical companies, earning in upfront money more than 10 times what investors put into the Boston-based biotech.